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Abstract
Background: Hydnophytum formicarium Jack is an epyphytic shrub that belongs to the family of Rubiaceae and is 
native to the tropical rain forests of the Asean region, which includes Malaysia. A flavanoid derivative, 7, 3', 5'-
trihydroxyflavanone (3HFD), isolated from H. formicarium has been reported to have cytotoxic effects on the human 
breast carcinoma cell line MCF-7. The aim of the current study was to investigate the mode of cell death in MCF-7 cells 
treated with 3HFD. A DNA fragmentation assay was conducted on isolated genomic DNA, a TUNEL assay was used to 
determine the mode of cell death and Western blotting was used to evaluate the expression levels of Bax and Bcl-2. 
Immunofluorescence staining of MCF-7 cells was also performed to confirm the up-regulation of the Bax protein.
Results: The ladder pattern resulting from the DNA fragmentation assay was a multimer of 180 kb. The morphological 
changes of cells undergoing apoptosis were visualised by a TUNEL assay over time. The percentage of apoptotic cells 
increased as early as 6 hours post treatment compared to untreated cells. Western blotting revealed up-regulation of 
the pro-apoptotic protein Bax. However, 3HFD did not affect expression of the anti-apoptotic protein Bcl-2.
Conclusions: Our results provide evidence that plant-derived 3HFD was able to induce the apoptotic cell death of 
MCF-7 cells by increasing Bax expression level and makes 3HFD a promising agent for chemotherapy, which merits 
further study.
Background
The tropical rain forests of Malaysia are known to be one
of the most diverse forests for medicinal plants that may
provide compounds for future anticancer therapies. It has
been estimated that 250,000 species of flowering plants
exist in the world. 150,000 of these species are found in
Malaysian tropical rain forests [1]. Unfortunately, only
7.8% of these plants have been investigated for pharmaco-
logically active compounds [2]. In the fight against cancer,
novel chemotherapeutic agents are constantly being
sought to complement existing drugs [2].
Cancer is one of the most serious, complex and diverse
diseases. Modern treatments are effective at assaulting
cancer cells, but these treatments may have unforeseen
complications on neighbouring normal cells. The efficacy
and safety of these treatments depends on the narrow
therapeutic index that rates a drug based on its lethal
dose and its therapeutic dose. The potential of plant rem-
edies acting upon established malignancies is apparently
limited. In 1955, screening of plant extracts for anti-can-
cer activity by the National Cancer Institute, United
States demonstrated that less than four of every one
thousand plant extracts tested contain compounds that
demonstrate efficacy as anti-cancer agents. The efficacy
and safety of these treatments depends on their ability to
selectively target tumour cells [3].
However, epidemiological studies have revealed that
eating a large amount of food from plant sources reduces
the risk of cancer [4]. Therefore, identifying anti-cancer
compounds in plant extracts has become a major effort
recently. For example, Styrylpyrone Derivative (SPD)
from the Goniothalamus sp. showed a profound anti-pro-
liferative effect on a human breast cancer cell line (MCF-
7) without cytotoxic effects on non-malignant cell lines
(Chang Liver and MDBK) [5]. Plant extracts containing
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Page 2 of 6coumarins [6], flavanoids [7], acridone alkaloids [8] and
diterpenes [9] have all been reported to have anti-cancer
effects.
The plant botanically known as Hydnophytum formi-
carium Jack from the family Rubiaceae, which is native to
Malaysia and Indonesia [10], has been investigated for
anti-cancer properties [11]. Traditionally, this plant has
been used to cure heart problems, treat chest pains and as
an anti-inflammatory remedy [12]. A flavanoid deriva-
tive, 7, 3', 5'-trihydroxyflavanone (3HFD), was extracted
from H. formicarium and was shown to have a potent
anti-proliferative activity [11]. Although the number of
studies on plant-derived anti-cancer agents is growing,
the precise mechanism of plant-derived agents on the
inhibition of cancer cell growth is not completely under-
stood. Previous studies have reported that aberrant
expression of the apoptosis-regulating genes from the
Bcl-2 family contributes significantly to the pathogenesis
of cancer. Hence, in this study, the mode of cell death
induced by 3HFD treatment was evaluated in the human
breast cancer cell line, MCF-7.
Results
DNA fragmentation analysis of MCF-7 cells treated with 
3HFD
Reduction in MCF-7 cell viability [11] following treat-
ment with 3HFD suggested the possibility of cell death.
Figure 1 shows the treatment of MCF-7 cells with 3HFD
based on the IC50 that was predetermined by an anti-pro-
liferative assay [11]. According to Kerr and Harmon,
DNA fragmentation is one of the hallmarks of apoptotic
cell death that is induced by most anticancer agents [13].
Visualisation of DNA laddering, indicative of DNA frag-
mentation (Figure 1), was only significant when a large
number of cells in a sample were engaged in the apoptotic
death pathway; therefore, a different method of identify-
ing these apoptotic cells was required. In the current
study, we confirmed the presence of DNA fragmentation
in cells treated with 3HFD by TUNEL (TdT-mediated
dUTP Nick End Labelling) assay.
The TUNEL assay was developed as a method to iden-
tify individual cells that were undergoing apoptosis by
labelling the ends of degraded DNA with the polymerase
terminal deoxynucleotidyl transferase (TdT) [14], which
catalyses the template-independent addition of deoxynu-
cleotide triphosphates to the 3'-OH ends of DNA. In this
study, 3HFD-treated cells were labelled using the TUNEL
assay (Figure 2) to examine the morphology of the cells
and to determine if DNA fragmentation occurs as a result
of 3HFD. Generally, apoptotic cells exhibit small nuclei
and have condensed chromatin. Eventually, the nuclear
membrane disappears and membrane blebbing produces
apoptotic bodies that contain cellular organelles and
chromatin, as observed at 24 to 72 hours post 3HFD
treatment (Figure 2D-F).
The percentage of apoptotic cells was determined by
direct visualisation by fluorescence microscopy in 3 inde-
pendent experiments (Figure 3). 3HFD treatment
resulted in a 20% increase in the number of apoptotic
cells after 6 hours compared to untreated cells.
Expression of pro- and anti-apoptotic proteins in MCF-7 
cells treated with 3HFD
The expression of the pro-apoptotic protein Bax is an
early event that sensitises the cell to undergo apoptosis.
Some models suggest that Bax up-regulation alone can
commit a cell to apoptosis [15]. Cells treated with 3HFD
exhibited a marked increase in fluorescence intensity
(Figure 4A-D) when stained with a specific Bax antibody
compared to controls. This result suggests that Bax
expression is up-regulated (Figure 5A-B) in cells follow-
ing treatment with 9 μg/ml 3HFD [11]. However, the anti-
apoptotic, Bcl-2 levels were very low throughout the
treatment period. Fragmentation of DNA, increasing lev-
els of apoptosis and up-regulation of the pro-apoptotic
Bax protein suggests a Bax-dependent apoptotic mecha-
nism induced by 3HFD.
Figure 1 DNA fragmentation analysis of MCF-7 cells treated with 
3HFD. Results of the DNA fragmentation analysis are presented as fol-
lows: untreated (lane 2); treated with 15 μg/ml of 3HFD for 72 h (lane 
3); treated with 9 μg/ml of 3HFD for 12 h (lane 4), 24 h (lane 5), 48 h 
(lane 6) or 72 h (lane 7). Comparison with 100 bp (lane 1) and 1 kb (lane 
8) molecular markers from Promega™ showed that lanes 4-7 were re-
peated fragments at 180 and 360 bp, whereas lane 3 exhibited a differ-
ent fragmentation pattern with no bands corresponding to either 360 
bp or 2400 bp were observed. This banding pattern may be explained 
by the detachment of the cells from the monolayer after 72 hours of 
incubation, because the cells lost the small fragment and the bigger 
fragment was not yet generated. The 180 bp fragments were weakly 
detected.
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The need to develop more effective and less toxic anti-
cancer drugs has prompted researchers to explore new
sources of pharmacologically active compounds. This
necessity is particularly important for more widespread
types of cancers, such as lung, colon and breast cancers.
Presently, chemotherapy and hormone compounds are
not completely effective due to the non-specific mecha-
nisms of action, non-specific and the presence of resis-
tant cancer cells [16].
A natural product provides novel structural specialities
that may qualify for new anti-cancer drugs. 3HFD, a com-
pound isolated from H. formicarium, has cytotoxic
effects against breast cancer cells similar to tamoxifen
[11] without affecting normal cell lines, such as Chang
Liver, Vero and MDBK. In this study, 3HFD was further
investigated for the mode of cell death that reduced can-
cer cell viability. The data obtained from this study
revealed that 3HFD induced apoptotic cell death.
The first morphological changes of apoptosis found in
most cell types are contraction in cell volume and con-
densation of the nucleus, which allows the intracellular
organelles, such as mitochondria, to retain their normal
morphology. This change is followed by plasma mem-
brane blebbing and nuclear fragmentation to form apop-
totic bodies [17]. A closer look at the pattern of TUNEL
staining in 3HFD treated MCF-7 cells suggests that DNA
fragmentation is initiated at the nuclear periphery as
described by Gavrielli et al. [14] and progresses towards
the centre (Figure 1A-F) as observed in Kataoka and Tsu-
ruo [17]. While TUNEL enables a determination of the
fraction of cells undergoing apoptosis, DNA forms a
characteristic laddering pattern on agarose gel electro-
phoresis that represents the biochemical changes
involved in the fragmentation of chromosomes into
nucleosome units [14]. As shown in Figure 1, multiple
units of apoptotic DNA laddering were detected in
3HFD-treated MCF-7 that increased with the duration of
Figure 2 TUNEL labelling of MCF-7 cells. Untreated and 3HFD-treat-
ed cells were labelled using the TUNEL assay to detect DNA fragmen-
tation. (A) In untreated cells, no fluorescence was detected in the 
nucleus, as the cells were not apoptotic and did not exhibit DNA frag-
mentation. (B) to (F) MCF-7 cells were treated with 9 μg/ml 3HDF for 6, 
12, 24, 48 or 72 hours, respectively. Cells exhibit DNA fragmentation 
and nuclear condensation, characteristic of apoptosis. Arrows indicate 
representative apoptotic cells.
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Figure 3 Apoptosis levels as determined by TUNEL assay. 3HFD 
treatment (9 μg/ml) significantly increased the level of apoptosis in 
MCF-7 cells as compared to untreated controls. Cells were observed 
up to 72 h after 3HFD treatment. Results are presented as the mean ± 
SEM of 3 independent experiments.
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Figure 4 Immunofluorescence staining of Bax protein in MCF-7 
cells treated with 9 μg/ml 3HFD. (A) Untreated MCF-7 cells at 0 h of 
3HFD treatment showed a low level of Bax protein. (B), (C) and (D) MCF-
7 cells after 6, 12 or 24 h of 3HFD treatment exhibited a marked in-
crease of immunofluorescence for Bax protein.
A
D
B
C
Abdullah et al. Cancer Cell International 2010, 10:14
http://www.cancerci.com/content/10/1/14
Page 4 of 6treatment. This result was in agreement with the results
obtained in the TUNEL assays and is illustrated by the
increasing apoptotic scores (Figure 3) from approxi-
mately 20% at 6 hours to approximately 83% at 72 hours.
These findings suggest that fully degraded nuclei are
cleared from the cell. After a certain point, the change in
gel electrophoresis pattern reflects only the ongoing
intracellular activity of the putative endonucleases [18].
In this study, oligonucleosomal DNA laddering was
observed. However, the laddering pattern shown by
MCF-7 cells treated with 3HFD did not produced high
molecular weight DNA fragments. Factors affecting lyso-
somal degradation are dependent on cell type and tissue
[13]. This result was reported by Grem et al. [18], who
studied MCF-7 and HL 60 cells treated with Pyrazolo-
acridine (PZA). When MCF-7 cells were treated with
PZA, the laddering pattern was similar to the pattern
observed in this study. In contrast, DNA fragmentation in
HL-60 cells treated with PZA exhibited classic oligonu-
cleosomal laddering as early as 6 hours after treatment
with 10 and 25 μM PZA [18]. The production of
megabase-sized DNA fragments is reported to be associ-
ated with the detachment of cells from the monolayer and
decreased cell volume that does not disturb membrane
integrity [19]. This might explains the current situation
when, after 72 hours at a 2-fold higher concentration of
3HFD treatment, more than 80% of cells were TUNEL-
positive, showing rapid DNA fragmentation, but with a
lower percentage of cells detached from the substrate.
Treatment of epithelial cancer cell lines with a specific
DNA-damaging agent will produce high molecular
weight DNA fragmentation in the absence of
nucleosomal laddering [20-22]. Within the current study,
the status of 3HFD as a DNA-damaging agent is unclear.
To confirm this, a DNA synthesis study is needed to
detect the relationship between inductions of parental
DNA double stranded in concert with single-strand
breaks [19].
Other than therapeutic agents that induce apoptosis,
molecules that have been strongly implicated as major
players in apoptosis are the bcl-2 oncogene [23] and Bcl-2
family proteins. The bax-α mRNA encodes the Bax pro-
tein, which promotes apoptosis due to its ability to form
heterodimers with bcl-2 [24]. It has been reported that
the bcl-2 gene is expressed in breast cancer cells [25], and
the level of expression varies with alteration of some
apoptotic stimuli [26]. Loss of bcl-2 gene expression has
been linked to poor patient prognosis. However, it has
not yet been determined whether bcl-2 or bcl-2 related
genes play any role in the development of breast cancer
[25]. Thus, in this study we have investigated the expres-
sion of Bax and Bcl-2 protein in MCF-7 cells treated with
3HFD.
In many human cancers, the anti-apoptotic Bcl-2 pro-
teins are over expressed, or the pro-apoptotic proteins,
like Bax, have reduced expression [27]. This results in
resistance to a wide variety of cell death stimuli including
chemotherapeutic drugs [28]. Bcl-2 protects against
diverse cytotoxic insults, including γ and UV-irradiation,
cytokine withdrawal, dexamethasone, staurosporine and
cytotoxic drugs, while pro-apoptotic family members like
Bax may act as tumour suppressors [29]. Therefore, find-
ing new cytotoxic agents that are able to increase Bax
expression or restore the ability of tumour cells to
undergo apoptosis are vital. Our data demonstrate that
3HFD treatment down-regulated Bcl-2 and significantly
up-regulated the expression of Bax in MCF-7 cells. Before
3HFD treatment, a low level of Bax was expressed in
MCF-7 cells, as observed in Strobel et al. [30]. They
reported that over expression of Bax in MCF-7 cells
resulted in increased sensitivity to apoptosis.
Figure 5 Western blot analysis of Bax protein in MCF-7 cells treat-
ed with 9 μg/ml 3HFD. (A) MCF-7 cells treated with 9 μg/ml 3HFD for 
the indicated times were resolved on a 15% PAGE and subjected to 
Western blotting. Bax protein expression increased as early as 3 h post 
treatment, whereas Bcl-2 levels were not altered and remained low 
throughout the experiment. (B)The intensity of Bax protein expression 
increased in a time-dependent manner. Results are presented as the 
mean ± SEM of 3 independent experiments.
          
        
       
    
    
A   
42 kDa ß-actin
26 kDa Bcl-2
21 kDa Bax
3 6 12 48h240
0
50
100
150
200
250
0 6 12 24
Hours post 3HFD treatment
R
el
at
iv
e 
de
ns
ito
m
et
ric
 u
ni
t f
or
 B
ax
3HFD 9 µg/ml
B
Abdullah et al. Cancer Cell International 2010, 10:14
http://www.cancerci.com/content/10/1/14
Page 5 of 6Although the mechanism for activating the expression
and function of Bcl-2, Bcl-XL and Bax is not fully under-
stood, it is possible that the p53 molecule plays a role in
this process [30]. This was demonstrated by the ability of
wild-type p53 to down-regulate Bcl-2 and up-regulate
Bax and proceed to programmed cell death [31-33]. The
p53 status is dependent on the anticancer agent and type
of cell line used. For example, SPD treatment bypasses the
p53 mediated pathway in the ovarian cancer cell line
Caov-3 [33]. This finding suggests that p53 might play a
role in the regulation of apoptosis by SPD rather than
through an elevation in p53 levels. In breast cancer cells,
activity of p53 may initiate apoptosis without transcrip-
tion [32].
3HFD treatment inhibits MCF-7 cell proliferation by
inducing apoptotic cell death. The up-regulation of Bax
protein expression suggests that 3HFD might be a poten-
tial anti-cancer agent in breast carcinoma. Additionally,
3HFD is part of a flavanoid group that may have estro-
genic potency especially for the human estrogen receptor
(ER) type Erβ as reported by George et al. [34]. This fla-
vanoid group is thought to play a beneficial role in pre-
venting breast cancer by competing with estrogens for
binding to estrogens receptor (ER) [35].
Conclusions
Our study demonstrates that 3HFD induced apoptosis in
MCF-7 cells. Apoptosis was caused by decreasing the
level of the anti-apoptotic protein Bcl-2 and up-regula-
tion of pro-apoptotic Bax. This compound was also selec-
tive for MCF-7 cells because no effect was observed in
non-malignant cell lines.
Methods
Cell culture
The cancer cell line MCF-7, and the non-cancerous cell
lines MDBK, Chang Livers and Vero, were obtained from
American Type Culture Collection (ATCC). MCF-7,
MDBK and Chang Liver cells were maintained in DMEM.
Vero cells were maintained in RPMI. DMEM and RPMI
were supplemented with 5% foetal calf serum (FCS), pen-
icillin-streptomycin and fungizone GIBCO™, Invitrogen.
DNA fragmentation assay
The isolation of genomic DNA from treated cells was
done as described by the manufacturer's protocol using
DNAzol® (Molecular Research Center Inc, USA). The iso-
lated DNA was analysed on a 1.5% agarose gel, stained
with ethidium bromide and viewed under Alpha Imager
Image Viewer. The agarose gel was photographed and
analysed.
Apoptotic index
The morphological changes and apoptotic index of
treated cells were analysed by TdT-mediated dUTP nick
labelling (TUNEL) with the Apoptosis Detection Kit, Flu-
orescein (Promega) according to the manufacturer's pro-
tocol. To calculate the percentage of TUNEL positive
cells, we counted cells from four random microscopic
fields at 100× and 400× as described in [5].
Immunofluorescence staining of Bax
Treated and untreated cells were fixed on slides and per-
meabilised with 0.2% Triton-X 100 for 20 min at 4°C.
Then, slides were blocked with 2% foetal calf serum in
PBS for 2 h at 37°C. After washing, cells were incubated
overnight with monoclonal anti-Bax antibodies
(Pharmingen) at a 1:200 dilution at 4°C. Next the slides
were incubated with FITC conjugated secondary anti-
bodies. Following washes, the slides were visualised with
a fluorescence microscope.
Western blotting
Protocols were slightly modified from [5]. Protein ali-
quots of 20 μg from both treated and untreated cells were
separated on 15% SDS-polyacrylamide gels. The sepa-
rated proteins were transferred onto polyvinyl-difluoride
membranes (PolysScreen, Nen Life Science). The mem-
branes were dried, preblocked in 5% non-fat milk in
phosphate-buffered saline and 0.1% Tween-20 and incu-
bated with primary antibody for Bax or Bcl-2 (Pharmin-
gen) at a 1:1500 dilution. This was followed by incubation
with horseradish peroxidase-labelled secondary antibod-
ies to mouse IgG and detection on a Kodak BIOMAT x-
ray film. Densitometry analysis was performed with a GS
670 Imaging Densitometer with the Molecular Analyst
Software (BioRad, Hercules, USA). The membranes were
reprobed with β-actin (Sigma) antibodies as an internal
control
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